The survival benefit of anti-HER2 treatment in the management of small (T1mic, T1a, T1b, T1c), node-negative HER2+ breast cancer

2022

Johnson KCC, Ni A, Grimm M, Sardesai SD, Stover DG, Cherian MA, Gatti-Mays ME, Pariser A, Sudheendra PK, Williams NO, VanDeusen JB, Ramaswamy B, Wesolowski R